Erik Wagner

11 Williams Ln.
Yardley, PA 19067
Cell Ph. (732) 927-6506
E-Mail: ew51419c@westpost.net
Goal: To find a position requiring considerable innovation and technical knowle
dge of biochemical assays, cellular biology and drug development methods
Education:
B.S. Microbiology, Indiana University, Bloomington, IN 1991.
Relevant Work Experience:
4/96-1/2010: Senior Research Scientist, Neuroscience, Wyeth Research (Now Pfi
zer), Monmouth Junction, NJ.
Duties: Performed research on an Alzheimer's Disease project to measure prote
ase inhibitor activity of compounds from corporate libraries and combinatorial
arrays. Responsible for creating and validating secondary and tertiary scr
eening assays (ELISAs, Toxicity assays, Western blot assays, and radiolabelled
cellular assays (SDS-PAGE)) to enable lead optimization. Responsible for des
igning and maintaining in-lab databases of compound characteristics and maintain
ing data on an Oracle intranet database. Responsible for maintaining cell cultu
re lab, creating stable transformed cell lines, and cell banking. Supervised th
e research activities of two junior scientists.
Accomplishments: Developed and managed several compound screens that identified
lead compounds in 2 separate programs. Converted several low throughput cellula
r assays into automated assays using robotics and template analysis. Developed
characterization assays that provided data for FDA NDA submission. Developed dat
a management tools that enabled SAR and rational drug design. Expressed full le
ngth proteins from cDNA encoding novel receptors. Successfully managed a resear
ch team that contributed substantially to the discovery of a class of successful
BACE inhibitors which were subsequently developed into clinical candidates.
Investigated novel mechanism of amyloid removal via upregulation of brain fibri
nolysis and showed pharmacological activity of test compounds in-vivo.
5/1991-4/1996 Associate Research Scientist, Protein Chemistry Department, Unigen
e Laboratories, Fairfield, NJ.
Duties: Performed research to develop novel oral formulations of salmon calciton
in. Used RIA, ELISA, and HPLC analysis of samples generated by in-vivo and in-v
itro drug transport models to determine delivery potential of formulations. Wa
s responsible for experimental design, analysis of data, and execution of studie
s to generate bioavailability and stability data to support an INDA filing. Als
o responsible for creating database of formulations to enable formulation optimi
zation. Also worked extensively in the area of protein purification to provide
source of Endothelin Cleaving Enzyme (ECE) for a Cleavage/ELISA ECE screen that
Unigene developed and marketed.
Accomplishments:
Developed and validated an RIA to quantitate salmon calcitonin in rat, dog, or h
uman plasma.
Developed fluorescence derivatization methods to allow HPLC detection of micromo
lar concentrations of peptide. Developed a canine infusion model and an Intesti
nal/Venous Access Port model for calcitonin distribution and metabolism followin
g oral dosing. Developed CACO2 cell paracellular transport assay for screening
potential transport enhancers. Developed reproducible purification for generati
ng enzyme to be used in automated high throughput screen for inhibitors
Specific Areas of Competence:Design and optimization of bioanalytical assays (EL
ISA,FRET,SPA, ECL immunoassays), protein purification, affinity chromatography,
Gel-based methods (Western blots, autoradiographic assays) antibody characteriz
ation and epitope mapping, in vitro translation/transcription (TNT). In-gel Wes
terns (LICOR), HPLC (analytical), Liquid Chromatography, Solid Phase Extractio
n (SPE), design and validation of primary, secondary, and tertiary screening as
says and toxicity assays. Design of biological databases and automatic data an
alysis templates for reporting.

Full Papers (Titles are hyperlinked to actual article where available)

Design and Synthesis of 5,5'-Disubstituted Aminohydantoins as Potent and Selecti
ve Human Beta-Secretase (BACE1) Inhibitors. Malamas MS, Erdei J, Gunawan I, Tur
ner J, Hu Y, Wagner E, Fan K, Chopra R, Olland A, Bard J, Jacobsen S, Magolda RL
, Pangalos M, Robichaud AJ. J Med Chem. 2009 Dec 7.
Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as pote
nt beta-secretase (BACE1) inhibitors. Nowak P, Cole DC, Aulabaugh A, Bard J, Ch
opra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, M
anas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K,
Turner J, Wagner E, Zhou P, Ellingboe JW. Bioorg Med Chem Lett. 2009 Nov 20.
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
Malamas MS, Erdei J, Gunawan I, Barnes K, Johnson M, Hui Y, Turner J, Hu Y, Wagn
er E, Fan K, Olland A, Bard J, Robichaud AJ. J Med Chem. 2009 Oct 22;52(20):631
4-23.
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyl
oid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A
, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E
, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW,
Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet
C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS. J Pharmacol E
xp Ther. 2009 Nov;331(2):598-608. Epub 2009 Aug 11.
Enhanced Clearance of Abeta in Brain by Sustaining the Plasmin Proteolysis Casca
de. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, As
chmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM,
Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Ma
golda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN. Proc Natl Acad Sci U
S A. 2008 Jun 24;105(25):8754-9. Epub 2008 Jun 16.
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring sub
stituents extending into the S1 and S3 substrate binding pockets. Cole DC, Stock
JR, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, J
ennings LD, Jin G, Lohse PA, Malamas MS, Manas ES, Moore WJ, O'Donnell MM, Ollan
d AM, Robichaud AJ, Svenson K, Wu J, Wagner E, Bard J. Bioorg Med Chem Lett. 20
08 Feb 1;18(3):1063-6. Epub 2007 Dec 10.
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring sub
stituents extending into the S1' substrate binding pocket. Jennings LD, Cole DC,
Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R, Jin G, Manas ES, Fan KY, Malamas
MS, Harrison BL, Jacobsen S, Chopra R, Lohse PA, Moore WJ, O'Donnell MM, Hu Y,
Robichaud AJ, Turner MJ, Wagner E, Bard J. Bioorg Med Chem Lett. 2008 Jan 15;18
(2):767-71. Epub 2007 Nov 17.
Thiophene substituted acylguanidines as BACE1 inhibitors. Fobare WF, Solvibile
WR, Robichaud AJ, Malamas MS, Manas E, Turner J, Hu Y, Wagner E, Chopra R, Cowli
ng R, Jin G, Bard J. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5353-6. Epub 2007
Aug 11.
Beta -Amyloid peptide-induced apoptosis regulated by a novel protein containing
a g protein activation module. Kajkowski EM, Lo CF, Ning X, Walker S, Sofia HJ,
Wang W, Edris W, Chanda P, Wagner E, Vile S, Ryan K, McHendry-Rinde B, Smith SC
, Wood A, Rhodes KJ, Kennedy JD, Bard J, Jacobsen JS, Ozenberger BA. J Biol Che
m. 2001 Jun 1;276(22):18748-56. Epub 2001 Feb 20.

"Utility of Pharmacodynamic Measures for Assessing the Oral Biovailability of Pe

ptides. 1. Administration of Recombinant Salmon Calcitonin in Rats", Patrick J.
Sinko, Curtis L Smith, Laura T McWhorter, William Stern, Erik Wagner, James P. G
illigan, Journal of Pharmaceutical Sciences, Vol. 84, No. 11, November, 1995, pp
. 1374-1378.

Abstract Citations:
"Rapid Detection and Identification of Salmon Calcitonin in Plasma after Oral or
Gastrointestinal Administration of Recombinant Salmon Calcitonin", E Wagner, JP
Gilligan, LT McWhorter, V. Burkett-Pazel, PJ Sinko, W Stern, Pharmaceutical Res
earch, Vol. 11, No. 10, October 1994, p. S-19.
"Metabolism of Recombinant Salmon Calcitonin by Intestinal Segments from Rat Duo
denum, Ileum, and Colon", E Wagner, H Yu, LT McWhorter, JP Gilligan, PJ Sinko, W
Stern, Pharmaceutical Research, Vol. 11, No. 10, October 1994, p. S-408.
"Bioavailability of Recombinant Salmon Calcitonin Administered to Various Region
s of the Rat Intestine", E Wagner, LT McWhorter, JP Gilligan, C Smith, PJ Sinko,
W Stern, Journal of Bone Mineral Research, Vol. 9, Supplement 1, August 1994, p
. S-217.
"Pharmacokinetics of Salmon Calcitonin Following Site Specific Delivery in the R
at Intestine", LT McWhorter, CA Smith, E Wagner, LM Snyder, W Stern, Pharmaceuti
cal Research, Vol. 11., No. 10, October 1994, p. S-409.
"Enhanced Bioavailability of Recombinant Salmon Calcitonin in Rats: Regional Int
estinal Administration with Protease Inhibitors", JP Gilligan, CA Smith, LT McWh
orter, E Wagner, PJ Sinko, W Stern, Pharmaceutical Research, Vol. 11., No. 10,
October 1994, p. S-409.
"Determination of Intestinal Permeability of Recombinant Salmon Calcitonin", PJ
Sinko, P. Hu, E Wagner, A Sturmer, JP Gilligan, JP Gilligan, W Stern, Pharmaceut
ical Research, Vol. 10, No. 10, October 1993, p.S-293.

"Pharmacokinetics and Pharmacodynamics of Recombinant Salmon Calcitonin After In

traduodenal, Intravenous, and Subcutaneous Administration in Rats", JP Gilligan,
CA Smith, L Tyburski, E Wagner, W Stern, PJ Sinko, Pharmaceutical Research, Vol
. 10, No. 10. October 1993, p. S-383.
"Pharmacokinetics, Pharmacodynamics, and Absolute Oral Bioavailability of Recomb
inant Salmon Calcitonin in Dogs", PJ Sinko, CA Smith, P. Hu, E Wagner, L Tybursk
i, JP Gilligan, W Stern, Pharmaceutical Research, Vol. 10, No. 10,, October 1993
, p. S-384.